Keywords: Ocular pharmacotherapy, aldose reductase inhibitors, PKC inhibitors, VEGF inhibitors, ACE inhibitors, somatostatin analogues, intravitreal steroids.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Michaelson JC. Retinal circulation in man and animals (Thomas, Springfield, Illinois, 1954) 1–146.
Sorbinil Retinopathy Trial Research Group. A randomozed trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990;108(9):1234–1244.
Tomlinson DR. Mitogen-activated protein kinases as glycose transducers for diabetic complications. Diabetologia 1999;42:1271–1281.
Koya D and King GL. Protein Kinase C Activation and the development of diabetic complications. Diabetes 1998;47:859–866.
Danis RP, Bingaman DP, Jirousek M et al. Inhibition of intraocular neovascularisation caused by retinal ischemia in pigs by af PKC β inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39:171–179.
Aiello LP. Medical and pharmacologic treatment of diabetic macular oedema. AAO Subspecialty Day, Anaheim CA, November 15, —vol. 18, 2003.
The PKC-DRS study group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C beta inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005;54:2188–2197.
PKC-DRS2 Group. Effect of Ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221–2230.
Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102(4):647–661.
UKPD Study Group 38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Brit M J 1998;317(7160):703–712.
Wilkinson-Berka JL. Diabetes and retinal vascular disorders: role of the rennin angiotensin system. Expert Rev Mol Med 2004;6:1–18.
ETDRS Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS Report No 8. Ophthalmology 1991;98(5):757–765.
Poulsen J. The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond's disease. Diabetes 1953;2:7–1284, 722–733.
Baldysiak-Figiel A, Lang GK, Kampmeier J et al. Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia. J Endocrin. 2004;180:417–424.
Boehm BO, Lang GK, Jehle PM et al. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Met Res. 2001;33: 300–306.
Grant MB, Mames RN, Fitzgerald C et al. The efficacy of octreotide in the therapy of severe nonproliferative diabetic and early proliferative diabetic retinopathy. Diabetes Care 2000;23:504–509.
Poulaki V, Joussen AM, Mitsiades N et al. Insulin-like growth factor-I plays a pathogenic role in diabetic retinopathy. Am J Pathol 2004;165:457–469.
Cunningham ET Jr, Adamis AO, Altaweel M et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer for diabetic macular edema. Ophthalmology 2005;112(10):1747–1757.
Chun DW, Heier JS, Topping TM et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant macular edema. Ophthalmology 2006;113(10):1706–1712.
Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10):1695–1705.e6.
Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand 2006;84(6):722–733.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Bek, T. (2007). Pharmacotherapy of Diabetic Retinopathy. In: Mogensen, C.E. (eds) Pharmacotherapy of Diabetes: New Developments. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69737-6_24
Download citation
DOI: https://doi.org/10.1007/978-0-387-69737-6_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-69736-9
Online ISBN: 978-0-387-69737-6
eBook Packages: MedicineMedicine (R0)